CVS CVS · NYSE
$92.68 +0.34% (+$0.32)
Summary
40 / 100 · Bulios Score
What speaks for it
- It has been profitable 6 years in a row.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- Earnings per share fell by 25% a year over the last 3 years.
- Repaying its net debt would take 4.8 years of operating profit.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 1.2 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.2 USD for 1 USD of yearly profit. Over the last five years it was 25.5 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 8.4% a year over 5 years. Over the last 3 years it grew by 7.6% a year. For the next fiscal year analysts expect revenue to grow by 3.6%. Earnings per share fell by 25% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 86 USD
- Sales and administration 12 USD
- Taxes and other 0.8 USD
- Net profit 1.2 USD
Net profit, industry median (Medical - Healthcare Plans) 2.3 USD
Out of every 100 USD of revenue, 1.2 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 2.87%
- Paid out of profit
- 69%
You receive $2.66 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 35
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $111.2 is 20% above today's price. 85% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Pharmacy Revenue 59%
- Premiums 35%
- Front Store Revenue 5.5%
- Product and Service, Other 1.0%
By region
The company reports no revenue by region.
Pharmacy Revenue brings in 59% of revenue. Premiums grew fastest, by 15% a year.
Segments in detail